Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2009

View Archived Issues

Novel DNA repair inhibitors discovered by CSIC and CNIO for cancer treatment

Biovitrum claims leptin receptor antagonists

Somatostatin agonists reported by Biostatin for the treatment of cancer, inflammation and pain

Solvay has launched Creon in the U.S.

Novel PDE4 inhibitor K-34 shows effectiveness in chronic dermatitis in vivo

Novel monoclonal antibody against CD123 shows clinical potential in acute myeloid leukemia

Foresight presents preclinical FST-100 data from adenoviral conjunctivitis model

NexMed and Novartis terminate licensing agreement for NM-100060 for onychomycosis

FDA accepts for review NDA for Amylin, Lilly and Alkermes' exenatide in type 2 diabetes

Genfit presents update on phase II clinical trials of GFT-505

NanoBio completes USD 22 million series B financing round

WraSer to market SALVAT's Cetraxal for acute otitis externa in the U.S.

Genmab completes enrollment in pivotal study of Arzerra in CLL

Schering-Plough receives marketing approval in Japan for Remeron/Reflex in MDD

Schering-Plough receives marketing approval in Japan for Asmanex for bronchial asthma

Barusiban and atosiban compared in women undergoing controlled ovarian stimulation

ENGAGE, ENSURE trials show efficacy of fertility hormone corifollitropin alfa

Hsp90-targeted therapy potentially useful in triple-negative breast cancer

PDK-1 inhibitor OSU-03012 shows potential in benign and malignant schwanommas

Allon reports phase II davunetide intranasal results in schizophrenia

Amarin receives SPA agreement from FDA for phase III AMR-101 trial

Dharma reports results for drug delivery system with lidocaine and epinephrine

Yondelis approved in the Philippines for ovarian cancer and soft tissue sarcoma

Alimta approved in Europe as maintenance therapy for non-squamous NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...